Literature DB >> 25458737

A propensity-matched comparison of perioperative complications and of chronic kidney disease between robot-assisted laparoscopic partial nephrectomy and radiofrequency ablative therapy.

Sung Han Kim1, Eun-Sik Lee2, Hyeon Hoe Kim2, Cheol Kwak2, Ja Hyeon Ku2, Sang Eun Lee3, Sung Kyu Hong3, Chang Wook Jeong3, Seung Hyup Kim2, Jeong Yeon Cho2, Sung Il Hwang3, Hak Jong Lee3, Seok Soo Byun4.   

Abstract

OBJECTIVE: The study presents a matched-pair analysis of robot-assisted laparoscopic partial nephrectomy (RALPN) versus radiofrequency ablation (RFA) to compare the perioperative incidence of complications and chronic kidney disease (CKD).
METHODS: All 46 RFA and 206 RALPN cases from June 2005 to December 2011 were retrospectively reviewed from the medical records and were matched 1:1 based on propensity scores by sex, tumor size, tumor laterality of kidney, tumor location within the kidney, and clinical T stage. Hilar vessel clamping was performed in all RALPN patients. The estimated glomerular filtration rate was used to define the CKD of < 60 mL/minute/1.73 m(2) by the Modification of Diet in Renal Disease equation. All patients with baseline CKD or solitary kidney were excluded prior to the matching analysis. The complication was noted with modified Clavien grades ≥ 3. Statistical analysis was performed to compare the perioperative incidence of complications and CKD.
RESULTS: A total of 27 matched pairs of RFA and RALPN patients were enrolled for analyzing CKD and perioperative complications. The better general conditions, higher estimated blood loss and transfusion rates, and longer operative time and hospital stay were observed significantly in RALPN patients (p < 0.05). Matched analysis demonstrated that the incidences of both perioperative complications (p = 0.434) and of CKD (p = 0.500) were not significantly different. No complication higher than Grade 4 was detected in either group.
CONCLUSION: Despite the intraoperative renal ischemia and invasiveness of the procedure associated with RALPN, the incidence of perioperative complication and of CKD developing rates were statistically similar.
Copyright © 2014. Published by Elsevier Taiwan.

Entities:  

Keywords:  ablation techniques; laparoscopy; nephrectomy; pulsed radiofrequency ablation treatment; renal cell carcinoma

Mesh:

Year:  2014        PMID: 25458737     DOI: 10.1016/j.asjsur.2014.09.005

Source DB:  PubMed          Journal:  Asian J Surg        ISSN: 1015-9584            Impact factor:   2.767


  5 in total

1.  A Systematic Review and Meta-Analysis of Minimally Invasive Partial Nephrectomy Versus Focal Therapy for Small Renal Masses.

Authors:  Lin Dong; Wang You Liang; Lu Ya; Liu Yang; Wei Qiang
Journal:  Front Oncol       Date:  2022-05-26       Impact factor: 5.738

2.  Partial nephrectomy versus ablative techniques for small renal masses: a systematic review and network meta-analysis.

Authors:  Johannes Uhlig; Arne Strauss; Gerta Rücker; Ali Seif Amir Hosseini; Joachim Lotz; Lutz Trojan; Hyun S Kim; Annemarie Uhlig
Journal:  Eur Radiol       Date:  2018-09-25       Impact factor: 5.315

Review 3.  Focal therapy versus robot-assisted partial nephrectomy in the management of clinical T1 renal masses: A systematic review and meta-analysis.

Authors:  Young Eun Yoon; Hyung Ho Lee; Ki Hong Kim; Sung Yul Park; Hong Sang Moon; Seung Ryeol Lee; Young Kwon Hong; Dong Soo Park; Dae Keun Kim
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.889

Review 4.  Radiofrequency Ablation Versus Partial Nephrectomy in Treating Small Renal Tumors: A Systematic Review and Meta-Analysis.

Authors:  Xiaotao Yin; Liang Cui; Fanglong Li; Siyong Qi; Zhaoyang Yin; Jiangping Gao
Journal:  Medicine (Baltimore)       Date:  2015-12       Impact factor: 1.817

Review 5.  Determinant factors for chronic kidney disease after partial nephrectomy.

Authors:  Oscar D Martín; Heilen Bravo; Marcos Arias; Diego Dallos; Yesica Quiroz; Luis G Medina; Giovanni E Cacciamani; Raul G Carlini
Journal:  Oncoscience       Date:  2018-02-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.